TABLE 4.

Clinical disease stage scoring^a

Time of scoring (mo p.i.)	Score for indicated animal
	Orally inoculated group										Aerosol-inoculated group
	PO-1	PO-2	PO-3	PO-4	PO-5	PO-6	PO-7	PO-8	PO-9	PO-10	A-1	A-2	A-3	A-4	A-5	A-6
3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
9	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
10	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
12	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Termination of study	3	3	3	3	0	2	2	3	3	2
16											0	0	0	0	0	0
19											1	1	1	1	2	3
20											2	1	2	1	2	†
21											2	2	2	1	†	†
22											2	2	2	1	†	†
23											2	3	3	2	†	†
25											2	†	†	3	†	†
26											3	†	†	†	†	†

^aDeer were given a score of 0 to 4 for clinical disease at each time point when excreta samples were taken. 0, normal behavior; 1, subtle behavioral changes (diurnal rhythms and patterns of sleeping, feeding, and activity are altered); 2, mild but observable neurological deficits, commonly mild ataxia in the hindquarters; 3, early stage, behavioral changes continue, with early signs of deterioration and continued progression of ataxia; 3, late stage, gait abnormalities become pronounced; 4, neurological deficit progression, wide-legged stance, low-hanging head, piloerection, obvious signs of muscle wasting, and increased ataxia. The appetite and ability to eat and drink are intact, with dramatic increases often seen (2 to 3 times normal volumes). †, deer that died during the study.